* Not providing two way discourse/debate (and relying on formulaic programming) has prepared investors poorly for when the halcyon days are over and the tides starts going out... "So much for objective journalism. Don't bother to look for it here--not under any byline of mine; or anyone else ...
Read in context ›Moderna Stock (MRNA)
Track Moderna stock through TheStreet Pro's latest coverage, including articles, Daily Diary mentions, TheStreet Pro portfolio activity, contributor watchlist signals, and Pro price levels.
MRNA
Moderna
healthcare
At close
$225.00
▲ +28.00 (+14.21%)
Oct 9, 4:00 PM ET
After-hours
$225.45
▲ +0.45 (+0.20%)
Oct 9, 7:59 PM ET
Market Cap
$78.65B
P/E Ratio
—
1Y Return
+717.29%
EPS (TTM)
-$7.98
Read the latest TheStreet Pro articles mentioning Moderna, including market roundups, portfolio updates, trade ideas, and investing analysis.
Articles
69 articlesDaily Diary Mentions
6 mentionsThe Business Media Has Failed You More Tales From Nvidia: Hypothesis Creep and No Miracles (Issue #156!) I should have gone back to first principles. Gen AI does not think. It re-assembles content that was already produced by humans (which it often has taken without permission or compensation). This is why it needs to be “t…
Read in context ›That's a Wrap Tuesday's markets opened on weakness and never made a serious attempt at a rally despite what was a very strong auction of U.S. 10-Year Notes midday. The yield for the 10-Year Note went out at 4.30% for the day, as the S…
Read in context ›Cartoon of the Day * Of a CNBC-kind * As I vividly recall the picks of WBD , MRNA , TTD , ELF and so many more From Hedgeye:
Read in context ›More Tales From Nvidia: Just Like Moderna and Covid, AI Is Overdone Apropos to my Moderna post from this morning. Moderna MRNA was the bell of the ball 3-4 years ago, just like AI is now. Back then I was screaming about Moderna's share price (and, to some degree, its efficacy) like I am…
Read in context ›